NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Shares Bought by XTX Topco Ltd

XTX Topco Ltd raised its holdings in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) by 40.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 45,996 shares of the company’s stock after acquiring an additional 13,346 shares during the quarter. XTX Topco Ltd owned approximately 0.34% of NeuroSense Therapeutics worth $58,000 as of its most recent filing with the SEC.

Separately, Armistice Capital LLC purchased a new stake in NeuroSense Therapeutics during the second quarter worth approximately $1,774,000. 1.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Maxim Group reiterated a “hold” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 16th.

NeuroSense Therapeutics Price Performance

NASDAQ NRSN opened at $1.36 on Monday. The company has a fifty day moving average of $1.12 and a two-hundred day moving average of $1.03. NeuroSense Therapeutics Ltd. has a 1 year low of $0.51 and a 1 year high of $2.33. The company has a market capitalization of $18.59 million, a PE ratio of -1.60 and a beta of 1.38.

NeuroSense Therapeutics (NASDAQ:NRSN) last released its quarterly earnings results on Wednesday, December 18th. The company reported ($0.11) earnings per share (EPS) for the quarter.

NeuroSense Therapeutics Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.